As a consequence, over the last decades survivin has generated considerable interest as therapeutical target in cancer resulting in many studies that investigated the expression of survivin in malignant tumors, such as colon cancer, lung cancer, gastric cancer, renal cell carcinoma and many others [13], [15], [21], [35], [36]. This evidence concerns the gene BIRC5 and gastric cancer.